Top Markets
Coin of the day
Aeolus Pharmaceuticals, Inc. Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS
Rangering i aksjer #41595
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pulmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$15.21K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aeolus Pharmaceuticals, Inc. (AOLS)

Kategori

P/S-forhold for Aeolus Pharmaceuticals, Inc. (AOLS)
P/S-forhold per 2026 TTM: 0
Ifølge Aeolus Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Aeolus Pharmaceuticals, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter